V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230001522 | 230000806 | null | 69 | Adjuvant (A) | 2016-10-24 | 2016-10-24 | GEMCITABINE | N | Y | 230003331 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 230001523 | 230000809 | 1.74 | null | Palliative (P) | 2013-09-08 | 2013-11-05 | PEMBROLIZUMAB | 02 | N | 230003340 | CAPECITABINE + OXALIPLATIN |
| 230001524 | 230001586 | 1.57 | 56.6 | Adjuvant (A) | 2013-03-09 | 2013-04-21 | FEC | N | N | 230003454 | OXALIPLATIN + MDG |
| 230001525 | 230000816 | 0 | null | Adjuvant (A) | 2019-05-02 | 2019-06-03 | Irinotecan + Modified De Gramont | N | N | 230003771 | CAPECITABINE |
| 230001526 | 230000818 | 0 | -1 | Adjuvant (A) | null | 2019-03-28 | Docetaxel | 02 | Y | 230003846 | CAPECITABINE |
| 230001527 | 230000821 | 1.79 | 75.1 | Neo-adjuvant (N) | 2018-06-05 | 2018-07-04 | CAPECITABINE + OXALIPLATIN | 1 | N | 230003903 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 230001528 | 230000823 | 1.8 | 89 | Adjuvant (A) | 2017-09-17 | 2017-09-22 | Capecitabine + Cisplatin + RT | 02 | N | 230003913 | CETUXIMAB |
| 230001529 | 230000824 | 1.64 | 60.8 | Palliative (P) | 2017-01-04 | 2017-01-22 | Oxaliplatin + Modified de Gramont | N | N | 230003940 | IRINOTECAN + MDG |
| 230001530 | 230000828 | 1.62 | 89 | Adjuvant (A) | 2018-02-21 | 2018-03-19 | Mitomycin Intravesical | 2 | N | 230004137 | FLUOROURACIL |
| 230001531 | 230000830 | 1.69 | null | Palliative (P) | 2018-01-09 | 2018-05-07 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 230004260 | CHOP R |
| 230001532 | 230000832 | 1.7 | 73 | null | 2018-12-28 | 2018-12-29 | Fluorouracil 96hr infusion+R(4g/m2) | 02 | N | 230004340 | TRASTUZUMAB |
| 230001533 | 230000832 | null | null | Palliative (P) | 2016-03-09 | 2016-03-09 | Irinotecan + Modified De Gramont | N | N | 230004340 | SORAFENIB |
| 230001534 | 230001364 | 1.69 | 59.6 | Curative (C) | 2012-04-30 | 2016-12-22 | Cetuximab + FOLFIRI cycle 2 onwards | 2 | N | 230004622 | CISPLATIN |
| 230001535 | 230000835 | 1.57 | 65.6 | Palliative (P) | 2019-02-13 | 2019-02-16 | LENVATINIB | 2 | null | 230004650 | CAPECITABINE |
| 230001536 | 230000839 | 1.64 | 58.5 | Palliative (P) | 2016-05-13 | 2016-06-11 | TRASTUZUMAB | 02 | N | 230004751 | FEC |
| 230001537 | 230000844 | 1.59 | null | Adjuvant (A) | 2015-09-12 | 2015-09-12 | Docetaxel 100mg/m2 (21 day) | 02 | null | 230005102 | CAPECITABINE + RT |
| 230001538 | 230000844 | 1.73 | 71.8 | Curative (C) | 2016-01-02 | 2016-01-19 | CARBOPLATIN + ETOPOSIDE | N | N | 230005102 | CVP R |
| 230001539 | 230000847 | 1.55 | 71 | Adjuvant (A) | 2014-09-03 | 2014-09-03 | Docetaxel | N | N | 230005284 | CARBOPLATIN + PEMETREXED |
| 230001540 | 230000850 | 1.81 | 69.3 | Palliative (P) | null | 2017-02-24 | Capecitabine (14 day) + Irinotecan | N | N | 230005329 | CETUXIMAB |
| 230001541 | 230000853 | null | 68 | Palliative (P) | 2018-05-28 | 2018-05-28 | Rituximab | N | Y | 230005457 | METHOTREXATE HIGH DOSE |
| 230001542 | 230000856 | null | 92.9 | Curative (C) | 2016-03-22 | 2016-08-02 | Oxaliplatin + Modified de Gramont | N | Y | 230005495 | CAPECITABINE + OXALIPLATIN |
| 230001543 | 230000858 | 1.79 | 110.1 | Palliative (P) | 2019-02-01 | 2019-02-01 | Capecitabine | 02 | N | 230005517 | CVP R |
| 230001544 | 230000860 | 1.54 | 123 | Adjuvant (A) | 2016-07-25 | 2016-10-18 | Carboplatin + Paclitaxel (3 weekly) | N | N | 230005755 | BCG |
| 230001545 | 230001376 | 1.68 | null | Palliative (P) | null | 2018-01-29 | Cisplatin | N | null | 230005912 | PIXANTRONE |
| 230001546 | 230000865 | 1.63 | 52.5 | Adjuvant (A) | 2013-11-11 | 2013-11-29 | Methotrexate intrathecal | N | N | 230006101 | PACLITAXEL |
| 230001547 | 230000870 | 1.59 | 69.05 | Palliative (P) | 2018-03-23 | 2018-10-21 | Oxaliplatin + Modified de Gramont | N | N | 230006826 | VANDETANIB |
| 230001548 | 230000872 | 1.8 | 122 | null | 2015-10-14 | 2015-10-14 | Carboplatin + Pemetrexed | 02 | null | 230007118 | CAPECITABINE + RT |
| 230001549 | 230000875 | 1.59 | null | Curative (C) | 2014-12-27 | 2014-12-28 | Trastuzumab 21 day maintenance | N | N | 230007118 | OXALIPLATIN + MDG |
| 230001550 | 230000877 | 1.68 | 84 | Palliative (P) | 2017-03-05 | 2017-03-12 | Bevacizumab + Cape + Oxali 14day | 02 | N | 230007216 | CISPLATIN + RT |
| 230001551 | 230000879 | 1.67 | 90.6 | Palliative (P) | 2016-09-05 | 2017-01-10 | Irinotecan + Modified De Gramont | 2 | N | 230007340 | CYCLOPHOSPHAMIDE |
| 230001552 | 230001690 | 1.77 | 92.4 | Curative (C) | null | 2016-07-02 | Carboplatin + Etoposide iv&po | N | N | 230007459 | OXALIPLATIN + MDG |
| 230001553 | 230000881 | 1.54 | null | Neo-adjuvant (N) | 2017-12-18 | 2017-12-21 | Capecitabine + Oxaliplatin 21day | N | N | 230007468 | SORAFENIB |
| 230001554 | 230000883 | null | 85.2 | null | 2016-10-13 | 2016-10-14 | LENVATINIB | N | N | 230007490 | PACLITAXEL |
| 230001555 | 230000885 | 1.5 | -1 | Palliative (P) | 2018-03-08 | 2018-03-17 | Trastuzumab Subcutaneous | 2 | Y | 230007554 | DOXORUBICIN + IFOSFAMIDE |
| 230001556 | 230000890 | 1.7 | null | Palliative (P) | 2015-06-28 | 2015-07-05 | Capecitabine | N | null | 230007563 | TRIAL |
| 230001557 | 230000892 | 1.52 | 61.4 | Not known (9) | 2016-02-21 | 2016-03-05 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 230007606 | LENVATINIB |
| 230001558 | 230000893 | 1.67 | 87 | Palliative (P) | 2017-09-01 | 2017-09-22 | LENVATINIB | 01 | N | 230007623 | CTD |
| 230001559 | 230000896 | 1.7 | 84 | Palliative (P) | 2016-12-20 | 2017-01-03 | Capecitabine (14 day) + Irinotecan | 2 | N | 230008182 | SORAFENIB |
| 230001560 | 230000897 | 1.81 | 92.4 | null | 2016-05-17 | 2016-05-30 | CETUXIMAB | 02 | N | 230008259 | CARBOPLATIN + ETOPOSIDE |
| 230001561 | 230000899 | 1.8 | 95.6 | Palliative (P) | 2017-06-10 | 2017-06-10 | FLUOROURACIL + IRINOTECAN | 02 | null | 230008316 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 230001562 | 230000903 | 1.56 | null | Palliative (P) | 2017-02-02 | 2017-03-06 | TRASTUZUMAB | N | N | 230008396 | METHOTREXATE INTRATHECAL |
| 230001563 | 230000906 | 1.55 | 64 | Adjuvant (A) | 2017-09-29 | 2017-10-07 | CHOP R - 21 days | N | N | 230008421 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 230001564 | 230000910 | 1.8 | 90.8 | Palliative (P) | 2017-11-25 | 2017-11-26 | EOX | N | N | 230008715 | GEMCITABINE + PACLITAXEL |
| 230001565 | 230001692 | 1.72 | 72.8 | null | 2016-02-08 | 2016-02-09 | Trastuzumab Subcutaneous | 02 | N | 230008842 | RITUXIMAB |
| 230001566 | 230000911 | 1.68 | 57.75 | Neo-adjuvant (N) | 2017-08-28 | 2017-09-18 | Rituximab | N | N | 230009054 | TRASTUZUMAB |
| 230001567 | 230000913 | 1.85 | 92.1 | Palliative (P) | 2018-01-03 | 2018-04-30 | Oxaliplatin + Modified de Gramont | N | N | 230009139 | CISPLATIN + ETOPOSIDE |
| 230001568 | 230000917 | 1.66 | 56.6 | Palliative (P) | 2019-06-06 | 2019-10-02 | Bortezomib + Cyclophos + Dex | 02 | N | 230009388 | LENVATINIB |
| 230001569 | 230001603 | 1.57 | 105.6 | Palliative (P) | 2014-10-23 | 2014-10-24 | LENVATINIB | Y | N | 230009647 | CAPECITABINE + OXALIPLATIN |
| 230001570 | 230000922 | 1.87 | 94.3 | Curative (C) | 2016-06-20 | 2016-06-28 | Capecitabine | 02 | N | 230009672 | CARBOPLATIN + ETOPOSIDE |
| 230001571 | 230001397 | null | 108.3 | Palliative (P) | 2015-10-26 | 2015-10-26 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 230009744 | LEAM |